Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.07 -6.1%	$1.05	$0.86 ▼ $3.60	$64.81M	0.05	287,498 shs	199,313 shs
GLUE Monte Rosa Therapeutics	$4.91 -0.2%	$4.42	$3.21 ▼ $12.40	$302.01M	1.4	1.08 million shs	380,743 shs
INZY Inozyme Pharma	$3.99 +0.3%	$2.30	$0.72 ▼ $6.24	$257.60M	2.29	884,521 shs	432,495 shs
PVLA Palvella Therapeutics	$25.05 -5.2%	$23.76	$6.20 ▼ $29.27	$276.95M	-0.1	70,759 shs	223,837 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	0.00%	+6.54%	+8.57%	-9.52%	-57.78%
GLUE Monte Rosa Therapeutics	-2.57%	+6.49%	+21.78%	-21.53%	+18.27%
INZY Inozyme Pharma	+0.25%	-0.25%	+265.14%	+298.00%	-20.40%
PVLA Palvella Therapeutics	+4.34%	+12.47%	+14.27%	-3.82%	+2,641,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	2.3274 of 5 stars	3.7	0.0	3.9	1.7	0.6
GLUE Monte Rosa Therapeutics	2.2939 of 5 stars	3.4	1.0	2.0	3.3	0.6
INZY Inozyme Pharma	3.1612 of 5 stars	4.2	3.0	2.6	2.5	0.0
PVLA Palvella Therapeutics	3.9739 of 5 stars	4.6	0.0	2.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.33	Buy	$7.33	585.36% Upside
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	215.68% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	194.49% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	84.77% Upside

Current Analyst Ratings Breakdown

Latest ABOS, INZY, GLUE, and PVLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/10/2025	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/8/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$4.61 per share	N/A
GLUE Monte Rosa Therapeutics	$159.49M	1.89	N/A	N/A	$3.58 per share	1.37
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$2.27 per share	N/A
PVLA Palvella Therapeutics	$42.81M	6.47	N/A	N/A	$21.66 per share	1.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$52.37M	-$1.94	N/A	N/A	N/A	N/A	-32.99%	-27.99%	8/12/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$135.35M	$0.08	N/A	N/A	N/A	N/A	-62.68%	-38.83%	8/14/2025 (Estimated)
INZY Inozyme Pharma	-$71.17M	-$1.69	N/A	N/A	N/A	N/A	-88.42%	-57.02%	8/5/2025 (Estimated)
PVLA Palvella Therapeutics	-$24.54M	-$12.10	N/A	N/A	N/A	N/A	-80.93%	-59.55%	8/13/2025 (Estimated)

Latest ABOS, INZY, GLUE, and PVLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/13/2025	Q1 2025	ABOS Acumen Pharmaceuticals	-$0.56	-$0.48	+$0.08	-$0.48	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
3/27/2025	Q4 2024	ABOS Acumen Pharmaceuticals	-$0.47	-$0.62	-$0.15	-$0.62	N/A	N/A
3/20/2025	Q4 2024	GLUE Monte Rosa Therapeutics	-$0.37	$0.23	+$0.60	$0.23	$43.73 million	$14.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.14	10.43	10.43
GLUE Monte Rosa Therapeutics	N/A	6.03	6.03
INZY Inozyme Pharma	0.51	7.68	7.68
PVLA Palvella Therapeutics	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
GLUE Monte Rosa Therapeutics	79.96%
INZY Inozyme Pharma	88.30%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
GLUE Monte Rosa Therapeutics	6.90%
INZY Inozyme Pharma	12.18%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	55.81 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.44 million	Optionable
INZY Inozyme Pharma	50	64.56 million	57.05 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	10.50 million	N/A

ABOS, INZY, GLUE, and PVLA Headlines

Recent News About These Companies

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 13 at 8:39 AM | msn.com

Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings

June 13 at 3:01 AM | americanbankingnews.com

Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Average Target Price from Brokerages

June 13 at 2:11 AM | americanbankingnews.com

Cantor Fitzgerald Comments on PVLA FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Palvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic Malformations

June 9, 2025 | quiverquant.com

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025 | globenewswire.com

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

June 9, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts

June 8, 2025 | marketbeat.com

Toronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)

June 2, 2025 | marketbeat.com

Palvella Therapeutics Advances in Rare Skin Disease Therapies

May 31, 2025 | tipranks.com

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025 | globenewswire.com

Toronto Dominion Bank Takes Position in Palvella Therapeutics (NASDAQ:PVLA)

May 27, 2025 | marketbeat.com

Cantor Fitzgerald Predicts PVLA FY2025 Earnings

May 23, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Invests $7.85 Million in Palvella Therapeutics (NASDAQ:PVLA)

May 23, 2025 | marketbeat.com

Cresset Asset Management LLC Purchases New Holdings in Palvella Therapeutics (NASDAQ:PVLA)

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Takes $8.57 Million Position in Palvella Therapeutics (NASDAQ:PVLA)

May 19, 2025 | marketbeat.com

Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%

May 16, 2025 | aaii.com

Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position

May 16, 2025 | tipranks.com

Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...

May 16, 2025 | finance.yahoo.com

Palvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts

May 16, 2025 | marketbeat.com

Q1 2025 Palvella Therapeutics Inc Earnings Call Transcript

May 16, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, INZY, GLUE, and PVLA Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.07 -0.07 (-6.14%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.01 (+0.56%)

As of 07:56 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.91 -0.01 (-0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$4.92 +0.00 (+0.10%)

As of 05:34 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Inozyme Pharma NASDAQ:INZY

$3.99 +0.01 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.99 0.00 (0.00%)

As of 07:12 PM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$25.05 -1.37 (-5.19%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time